Alphamab Oncology banner

Alphamab Oncology
HKEX:9966

Watchlist Manager
Alphamab Oncology Logo
Alphamab Oncology
HKEX:9966
Watchlist
Price: 9.34 HKD 1.52% Market Closed
Market Cap: HK$9.1B

Alphamab Oncology
Investor Relations

Alphamab Oncology is an investment holding company. The company is headquartered in Suzhou, Jiangsu. The company went IPO on 2019-12-12. The firm is a full-industry chain enterprise specializing in research, development, manufacture, and commercialization of innovative tumor immunobiology macromolecular targeted drugs. The firm has bio-innovation drug development technology platform, including protein engineering platform, multi-functional antibody development platform and antibody screening platform. The firm operates its businesses in both domestic and overseas markets.

Show more
Loading
9966
Hang Seng (Hong Kong)
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
No Earnings Calls Available

Management

Dr. Ting Xu Ph.D.
Founder, Executive Chairman & CEO
No Bio Available
Ms. Yang Liu
VP of Corporate Operations & Executive Director
No Bio Available
Mr. Yumin Wan
Vice President of Government Affairs & Public Relations
No Bio Available
Dr. Mike Liu M.B.A., Ph.D.
Senior Vice President of Business Development
No Bio Available
Mr. Jing Han
Chief Commercial Officer
No Bio Available
Ms. Qiulan Cheng
Joint Company Secretary
No Bio Available

Contacts

Address
JIANGSU
Suzhou
No. 175, Fangzhou Road, Suzhou Industrial Park
Contacts